Kymera Investor Day Presentation Deck

First-in-class IRAK4(¹) oral protein degrader SAR444656 or KT-474 ● ● Degradation of IRAK4 protein abolishes its kinase activity and scaffold function ● IRAK4 protein degrader SAR444656 inhibits pNFkB and pro-inflammatory cytokines • Potential for oral immunology ● pathway drug across multiple indications Targeting early initiation steps may afford possibility of early intervention and disease modification IRAK4 Kinase Inhibitor SANOFI Inactive Kinase P IRF5/7 TLRs IRAK4 MyD88 IRAK4 scaffold function P NFkB | T IL1/IL18/IL33/IL36 IRAK4 Protein Degrader (SAR444656) Inactive Kinase Disabled scaffold function P IRF5/7 I I I IFNa/B, inflammatory cytokines (IL-6, TNFa) & mediators pNFkB (S536) Log2 (stim./unstim.) IL-6 (% control) 3 2 150- 100- 50- 0 -6 Mean (± SE) Percent IRAK4 Change from Baseline at 48hr 20 (SAR444656) * -20 -40 -60 -80 Potent inhibition of pNFkB in PBMC Kinase Negative Inhibitor -100 Degrader Control Potent Inhibition of TLR+IL1 induced cytokines in PBMC + -4 -2 0 Log (concentration, nM) Placebo Potent IRAK4 degradation in Human (PBMC) 25 mg SD 75 mg SD 150 mg SD CIXIO 300 mg SD *Significant dij *** IRAK4 expression is below level of quantification Degrader (SAR444656) Negative Control Kinase Inhibition 600 mg SD 1000 mg SD T 2 1600 mg SD Entered the clinic in 2021; Initial indications: Atopic Dermatitis and Hidradenitis Suppurativa IRAK4 is an asset under investigation and is not approved by any regulators, also called SAR444656 (1) IRAK4 protein degrader in collaboration with Kymera, also known as KT474 48

View entire presentation